In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for migaldendranib for the treatment of ...

Researcher works with universities of California-Davis, Illinois, Wisconsin and others to engineer and test a novel microsphere-hydrogel delivery for medicine, requiring fewer injections, to treat a c ...

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...

Researchers from the Karolinska Institutet in Sweden have found a potential new treatment for non-alcoholic fatty liver ...

A study reveals that repeated anti-VEGF injections for AMD do not alter retinal vascular metrics over time, ensuring ...

Programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF) are often co-expressed in the tumor microenvironment. The combination of anti-PD-1 and anti-VEGF agents has been ...

In late April, Summit Therapeutics revealed interim OS data from HARMONi-2 for its PD-1/VEGF bispecific antibody, ivonescimab ...

Researchers have discovered in an ongoing phase IIb trial that a single intravitreal injection of UBX1325 (foselutoclax), a ...

Researchers found the therapy downregulated VEGF expression and improved retinal thickness in neovascular age-related macular degeneration patients.

UNITY Biotechnology reveals promising 36-week results for UBX1325 in treating diabetic macular edema, showing non-inferiority ...